Skip to main content
OpenTrials
Completed

NCT Number: NCT03743038

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris (Study FX2018-23).

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Site #01

San Diego, California, 92123, United States

About this study

A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris. Eligible subjects will be randomized (1:1) to treatment with Test Article A to one side of the face versus Test Article B on the contralateral side.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has facial acne vulgaris with:

16 inflammatory lesions (papules, pustules) The inflammatory lesion count on the right and left side of the face should be similar IGA score of moderate (3) on both the right and left side of the face

Exclusion criteria

  • Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations.
  • More than two facial nodules/cysts
  • Sunburn on the face

Treatment and study plan

FMX101 vehicle

Drug

FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)

Other names: Test Article A

Hydro-alcohol solution

Other

Hydro-alcohol solution based vehicle (Test Article B)

Other names: Test Article B

Primary outcomes

  1. Number of Participants With 0 to 4 Investigator's Global Assessment Score at Week 6

    Time frame: At Week 6

    Severity of acne vulgaris was assessed by Investigator Global Assessment (IGA). The IGA score is a static evaluation of the overall severity or "average" degree of severity of a participant's disease by the Blinded Evaluator taking into account all of the participant's facial acne lesions as the participant appears on the day of the evaluation. Overall severity of acne was assessed using a five-point scale where 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Low score represented best outcome and higher score value indicated worst outcome.

  2. Number of Participants Achieving Investigator's Global Assessments Treatment Success at Week 6

    Time frame: At Week 6

    Severity of acne vulgaris was assessed by IGA. The IGA score is a static evaluation of the overall severity or "average" degree of severity of a participant's disease by the Blinded Evaluator taking into account all of the participant's facial acne lesions as the participant appears on the day of the evaluation. Overall severity of acne was assessed using a five-point scale where 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. The IGA treatment "success" was defined as at least a two-point improvement in IGA score relative to Baseline.

  3. Absolute Change From Baseline to Week 6 in Inflammatory Lesion Count

    Time frame: Day 1/ Baseline and Week 6

    Inflammatory lesion count (ILC) included papules (raised inflammatory lesions with no visible purulent material) and pustules (raised inflammatory lesions with visible purulent material).

  4. Percentage Change From Baseline to Week 6 in Inflammatory Lesion Count

    Time frame: Day 1/ Baseline and Week 6

    The ILC included papules (raised inflammatory lesions with no visible purulent material) and pustules (raised inflammatory lesions with visible purulent material).

  5. Absolute Change From Baseline to Week 6 in Non-Inflammatory Lesion Count

    Time frame: Day 1/ Baseline and Week 6

    The non-inflammatory lesion count (NILC) included open and closed comedones.

  6. Percentage Change From Baseline to Week 6 in Non-Inflammatory Lesion Count

    Time frame: Day 1/ Baseline and Week 6

    The NILC included open and closed comedones.

  7. Change in Sebum Percentage Relative to Baseline Versus Weeks 2, 4, 6 and 7

    Time frame: Day 1/Baseline and Weeks 2, 4, 6 and 7

    Sebum measurement was conducted on the right and left side of the face. The sebum measurement represented the sebum score of saturation of the film and had a range of 0 to 99, where 99 equated to very oily skin.

  8. Change in Transepidermal Water Loss Relative to Baseline Versus Weeks 2, 4, 6 and 7

    Time frame: Day 1/Baseline and Weeks 2, 4, 6 and 7

    Transepidermal Water Loss (TEWL) was conducted on the right and left side of the face.

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: Day 1 until Week 7 (End of Study) and Unscheduled Visit

    An adverse event is any untoward medical occurrence associated with the use of a drug in participants, whether or not considered drug related.

  10. Number of Participants Having Local Skin Reactions With Improved/Same Versus Worsened Severities Compared to Baseline

    Time frame: Day 1 until Week 7 (End of Study) or Unscheduled Visit

    The local skin reactions (LSRs) included erythema, edema, scaling/dryness, burning/stinging, pruritus, erosion, and pain) were assessed. Erythema, edema, scaling/dryness, and erosion were assessed by the investigator and burning/stinging, pain, and pruritus were assessed by the participant. Assessments was made using a 4-point ordinal scale where 0=absent, 1=mild (slight, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). Here, lower point represented no reaction and higher points represented severe reactions.The LSRs were assessed both before and 15 minutes following test article application.

Sponsors and collaborators

Lead sponsor

Vyne Therapeutics Inc.

Industry

Registry information

Official study title

A Randomized, Evaluator-Blinded, Bilateral Comparison Study of Two Topicals in the Treatment of Subjects With Acne Vulgaris

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 15, 2018
Registry last updated
Apr 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.